Alembic Pharmaceuticals (BOM:533573) Net Income From Continuing Operations : ₹6,158 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Alembic Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Alembic Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2024 was ₹1,782 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,158 Mil.

Alembic Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Alembic Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alembic Pharmaceuticals Net Income From Continuing Operations Chart

Alembic Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income From Continuing Operations

Get a 7-Day Free Trial

9,998.20

13,680.80

6,253.90

3,545.90

6,318.30

Alembic Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,525.90	1,206.10	1,365.60	1,804.50	1,782.10

Alembic Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,158 Mil.

Alembic Pharmaceuticals (BOM:533573) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

APLLTD:India

Address

Alembic Road, Vadodara, GJ, IND, 390 003

Website

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Alembic Pharmaceuticals (BOM:533573) Headlines

No Headlines